nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Vasculitis necrotising—Furosemide—dilated cardiomyopathy	0.0351	0.0365	CcSEcCtD
Methylphenidate—Hexylcaine—SCN5A—dilated cardiomyopathy	0.0246	0.686	CrCbGaD
Methylphenidate—Drug eruption—Spironolactone—dilated cardiomyopathy	0.022	0.0228	CcSEcCtD
Methylphenidate—Ulcer—Spironolactone—dilated cardiomyopathy	0.0143	0.0148	CcSEcCtD
Methylphenidate—Vasculitis—Spironolactone—dilated cardiomyopathy	0.0139	0.0144	CcSEcCtD
Methylphenidate—Local reaction—Furosemide—dilated cardiomyopathy	0.0133	0.0138	CcSEcCtD
Methylphenidate—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.0124	0.0129	CcSEcCtD
Methylphenidate—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.0121	0.0126	CcSEcCtD
Methylphenidate—Drug eruption—Furosemide—dilated cardiomyopathy	0.012	0.0124	CcSEcCtD
Methylphenidate—Eruption—Furosemide—dilated cardiomyopathy	0.012	0.0124	CcSEcCtD
Methylphenidate—Ipratropium bromide—SLC22A5—dilated cardiomyopathy	0.0112	0.314	CrCbGaD
Methylphenidate—Appetite absent—Lisinopril—dilated cardiomyopathy	0.0111	0.0115	CcSEcCtD
Methylphenidate—Apathy—Furosemide—dilated cardiomyopathy	0.0103	0.0107	CcSEcCtD
Methylphenidate—Ear disorder—Lisinopril—dilated cardiomyopathy	0.0102	0.0106	CcSEcCtD
Methylphenidate—Flat affect—Furosemide—dilated cardiomyopathy	0.0102	0.0106	CcSEcCtD
Methylphenidate—Lethargy—Spironolactone—dilated cardiomyopathy	0.01	0.0104	CcSEcCtD
Methylphenidate—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00885	0.00918	CcSEcCtD
Methylphenidate—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00879	0.00912	CcSEcCtD
Methylphenidate—Gastritis—Spironolactone—dilated cardiomyopathy	0.0087	0.00902	CcSEcCtD
Methylphenidate—Drug interaction—Furosemide—dilated cardiomyopathy	0.00794	0.00823	CcSEcCtD
Methylphenidate—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00782	0.00811	CcSEcCtD
Methylphenidate—Throat sore—Lisinopril—dilated cardiomyopathy	0.00767	0.00795	CcSEcCtD
Methylphenidate—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00767	0.00795	CcSEcCtD
Methylphenidate—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.0076	0.00788	CcSEcCtD
Methylphenidate—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00757	0.00785	CcSEcCtD
Methylphenidate—Vasculitis—Furosemide—dilated cardiomyopathy	0.00755	0.00783	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00751	0.00779	CcSEcCtD
Methylphenidate—Otitis media—Lisinopril—dilated cardiomyopathy	0.0071	0.00736	CcSEcCtD
Methylphenidate—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00691	0.00717	CcSEcCtD
Methylphenidate—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00677	0.00702	CcSEcCtD
Methylphenidate—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00643	0.00667	CcSEcCtD
Methylphenidate—Mental disability—Furosemide—dilated cardiomyopathy	0.00639	0.00663	CcSEcCtD
Methylphenidate—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00625	0.00648	CcSEcCtD
Methylphenidate—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00625	0.00648	CcSEcCtD
Methylphenidate—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00615	0.00637	CcSEcCtD
Methylphenidate—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.00612	0.00635	CcSEcCtD
Methylphenidate—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00609	0.00631	CcSEcCtD
Methylphenidate—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00608	0.0063	CcSEcCtD
Methylphenidate—Swelling—Furosemide—dilated cardiomyopathy	0.00606	0.00629	CcSEcCtD
Methylphenidate—Cough increased—Lisinopril—dilated cardiomyopathy	0.00604	0.00626	CcSEcCtD
Methylphenidate—Alopecia—Spironolactone—dilated cardiomyopathy	0.00601	0.00623	CcSEcCtD
Methylphenidate—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00596	0.00618	CcSEcCtD
Methylphenidate—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00569	0.0059	CcSEcCtD
Methylphenidate—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00567	0.00588	CcSEcCtD
Methylphenidate—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00566	0.00587	CcSEcCtD
Methylphenidate—Thirst—Furosemide—dilated cardiomyopathy	0.00562	0.00583	CcSEcCtD
Methylphenidate—Neck pain—Lisinopril—dilated cardiomyopathy	0.00559	0.0058	CcSEcCtD
Methylphenidate—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00549	0.00569	CcSEcCtD
Methylphenidate—Lethargy—Furosemide—dilated cardiomyopathy	0.00546	0.00566	CcSEcCtD
Methylphenidate—Malaise—Spironolactone—dilated cardiomyopathy	0.00534	0.00553	CcSEcCtD
Methylphenidate—Leukopenia—Spironolactone—dilated cardiomyopathy	0.0053	0.00549	CcSEcCtD
Methylphenidate—Irritability—Furosemide—dilated cardiomyopathy	0.0051	0.00529	CcSEcCtD
Methylphenidate—Discomfort—Spironolactone—dilated cardiomyopathy	0.00498	0.00516	CcSEcCtD
Methylphenidate—Dehydration—Furosemide—dilated cardiomyopathy	0.00497	0.00516	CcSEcCtD
Methylphenidate—Confusional state—Spironolactone—dilated cardiomyopathy	0.00487	0.00505	CcSEcCtD
Methylphenidate—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00483	0.00501	CcSEcCtD
Methylphenidate—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00481	0.00499	CcSEcCtD
Methylphenidate—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00473	0.0049	CcSEcCtD
Methylphenidate—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00463	0.00481	CcSEcCtD
Methylphenidate—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00461	0.00478	CcSEcCtD
Methylphenidate—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00459	0.00476	CcSEcCtD
Methylphenidate—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00457	0.00474	CcSEcCtD
Methylphenidate—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00453	0.0047	CcSEcCtD
Methylphenidate—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00453	0.00469	CcSEcCtD
Methylphenidate—Eczema—Lisinopril—dilated cardiomyopathy	0.00446	0.00463	CcSEcCtD
Methylphenidate—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.0044	0.00457	CcSEcCtD
Methylphenidate—Injury—Lisinopril—dilated cardiomyopathy	0.00436	0.00453	CcSEcCtD
Methylphenidate—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00433	0.00449	CcSEcCtD
Methylphenidate—Somnolence—Spironolactone—dilated cardiomyopathy	0.00429	0.00445	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00422	0.00437	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00417	0.00432	CcSEcCtD
Methylphenidate—Drowsiness—Furosemide—dilated cardiomyopathy	0.00412	0.00427	CcSEcCtD
Methylphenidate—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00411	0.00426	CcSEcCtD
Methylphenidate—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00409	0.00425	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00408	0.00424	CcSEcCtD
Methylphenidate—Diplopia—Lisinopril—dilated cardiomyopathy	0.00401	0.00416	CcSEcCtD
Methylphenidate—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00401	0.00416	CcSEcCtD
Methylphenidate—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00398	0.00413	CcSEcCtD
Methylphenidate—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00398	0.00413	CcSEcCtD
Methylphenidate—Sweating—Furosemide—dilated cardiomyopathy	0.00395	0.0041	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.0039	0.00404	CcSEcCtD
Methylphenidate—Urticaria—Spironolactone—dilated cardiomyopathy	0.00384	0.00398	CcSEcCtD
Methylphenidate—Irritability—Lisinopril—dilated cardiomyopathy	0.00383	0.00397	CcSEcCtD
Methylphenidate—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00382	0.00396	CcSEcCtD
Methylphenidate—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00381	0.00396	CcSEcCtD
Methylphenidate—Dehydration—Lisinopril—dilated cardiomyopathy	0.00373	0.00387	CcSEcCtD
Methylphenidate—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00365	0.00379	CcSEcCtD
Methylphenidate—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00363	0.00376	CcSEcCtD
Methylphenidate—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00362	0.00376	CcSEcCtD
Methylphenidate—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00361	0.00375	CcSEcCtD
Methylphenidate—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00359	0.00372	CcSEcCtD
Methylphenidate—Visual impairment—Furosemide—dilated cardiomyopathy	0.00356	0.0037	CcSEcCtD
Methylphenidate—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00356	0.00369	CcSEcCtD
Methylphenidate—Gastritis—Lisinopril—dilated cardiomyopathy	0.00355	0.00368	CcSEcCtD
Methylphenidate—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.0035	0.00363	CcSEcCtD
Methylphenidate—Influenza—Lisinopril—dilated cardiomyopathy	0.00347	0.0036	CcSEcCtD
Methylphenidate—Asthma—Lisinopril—dilated cardiomyopathy	0.00347	0.0036	CcSEcCtD
Methylphenidate—Eye disorder—Furosemide—dilated cardiomyopathy	0.00346	0.00358	CcSEcCtD
Methylphenidate—Pruritus—Spironolactone—dilated cardiomyopathy	0.00342	0.00354	CcSEcCtD
Methylphenidate—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.0034	0.00353	CcSEcCtD
Methylphenidate—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00338	0.0035	CcSEcCtD
Methylphenidate—Angiopathy—Furosemide—dilated cardiomyopathy	0.00336	0.00348	CcSEcCtD
Methylphenidate—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00334	0.00346	CcSEcCtD
Methylphenidate—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00333	0.00346	CcSEcCtD
Methylphenidate—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.0033	0.00343	CcSEcCtD
Methylphenidate—Arrhythmia—Furosemide—dilated cardiomyopathy	0.0033	0.00343	CcSEcCtD
Methylphenidate—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00329	0.00341	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00322	0.00334	CcSEcCtD
Methylphenidate—Erythema—Furosemide—dilated cardiomyopathy	0.00322	0.00334	CcSEcCtD
Methylphenidate—Malnutrition—Furosemide—dilated cardiomyopathy	0.00322	0.00334	CcSEcCtD
Methylphenidate—Dizziness—Spironolactone—dilated cardiomyopathy	0.00319	0.00331	CcSEcCtD
Methylphenidate—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00319	0.00331	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00316	0.00328	CcSEcCtD
Methylphenidate—Weight increased—Lisinopril—dilated cardiomyopathy	0.00316	0.00327	CcSEcCtD
Methylphenidate—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00314	0.00325	CcSEcCtD
Methylphenidate—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00311	0.00322	CcSEcCtD
Methylphenidate—Muscle spasms—Furosemide—dilated cardiomyopathy	0.0031	0.00321	CcSEcCtD
Methylphenidate—Depression—Lisinopril—dilated cardiomyopathy	0.00308	0.0032	CcSEcCtD
Methylphenidate—Vomiting—Spironolactone—dilated cardiomyopathy	0.00307	0.00318	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00306	0.00318	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00305	0.00316	CcSEcCtD
Methylphenidate—Rash—Spironolactone—dilated cardiomyopathy	0.00305	0.00316	CcSEcCtD
Methylphenidate—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00304	0.00316	CcSEcCtD
Methylphenidate—Vision blurred—Furosemide—dilated cardiomyopathy	0.00303	0.00315	CcSEcCtD
Methylphenidate—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00303	0.00314	CcSEcCtD
Methylphenidate—Headache—Spironolactone—dilated cardiomyopathy	0.00303	0.00314	CcSEcCtD
Methylphenidate—Anaemia—Furosemide—dilated cardiomyopathy	0.00298	0.00309	CcSEcCtD
Methylphenidate—Sweating—Lisinopril—dilated cardiomyopathy	0.00296	0.00307	CcSEcCtD
Methylphenidate—Agitation—Furosemide—dilated cardiomyopathy	0.00296	0.00307	CcSEcCtD
Methylphenidate—Haematuria—Lisinopril—dilated cardiomyopathy	0.00295	0.00306	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00292	0.00303	CcSEcCtD
Methylphenidate—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00292	0.00302	CcSEcCtD
Methylphenidate—Sinusitis—Lisinopril—dilated cardiomyopathy	0.0029	0.00301	CcSEcCtD
Methylphenidate—Vertigo—Furosemide—dilated cardiomyopathy	0.00289	0.003	CcSEcCtD
Methylphenidate—Leukopenia—Furosemide—dilated cardiomyopathy	0.00288	0.00299	CcSEcCtD
Methylphenidate—Nausea—Spironolactone—dilated cardiomyopathy	0.00287	0.00298	CcSEcCtD
Methylphenidate—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00283	0.00293	CcSEcCtD
Methylphenidate—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00278	0.00289	CcSEcCtD
Methylphenidate—Hallucination—Lisinopril—dilated cardiomyopathy	0.00276	0.00286	CcSEcCtD
Methylphenidate—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00275	0.00286	CcSEcCtD
Methylphenidate—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00274	0.00284	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00272	0.00282	CcSEcCtD
Methylphenidate—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00272	0.00282	CcSEcCtD
Methylphenidate—Dry mouth—Furosemide—dilated cardiomyopathy	0.00268	0.00278	CcSEcCtD
Methylphenidate—Confusional state—Furosemide—dilated cardiomyopathy	0.00265	0.00275	CcSEcCtD
Methylphenidate—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00263	0.00273	CcSEcCtD
Methylphenidate—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00262	0.00272	CcSEcCtD
Methylphenidate—Shock—Furosemide—dilated cardiomyopathy	0.00259	0.00268	CcSEcCtD
Methylphenidate—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00258	0.00267	CcSEcCtD
Methylphenidate—Flushing—Lisinopril—dilated cardiomyopathy	0.00258	0.00267	CcSEcCtD
Methylphenidate—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00257	0.00267	CcSEcCtD
Methylphenidate—Skin disorder—Furosemide—dilated cardiomyopathy	0.00255	0.00265	CcSEcCtD
Methylphenidate—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00254	0.00263	CcSEcCtD
Methylphenidate—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00252	0.00261	CcSEcCtD
Methylphenidate—Anorexia—Furosemide—dilated cardiomyopathy	0.0025	0.0026	CcSEcCtD
Methylphenidate—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.0025	0.00259	CcSEcCtD
Methylphenidate—Chills—Lisinopril—dilated cardiomyopathy	0.00249	0.00258	CcSEcCtD
Methylphenidate—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00248	0.00257	CcSEcCtD
Methylphenidate—Alopecia—Lisinopril—dilated cardiomyopathy	0.00245	0.00254	CcSEcCtD
Methylphenidate—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00243	0.00252	CcSEcCtD
Methylphenidate—Erythema—Lisinopril—dilated cardiomyopathy	0.00242	0.00251	CcSEcCtD
Methylphenidate—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00242	0.00251	CcSEcCtD
Methylphenidate—Tension—Lisinopril—dilated cardiomyopathy	0.00237	0.00246	CcSEcCtD
Methylphenidate—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00236	0.00245	CcSEcCtD
Methylphenidate—Nervousness—Lisinopril—dilated cardiomyopathy	0.00235	0.00243	CcSEcCtD
Methylphenidate—Back pain—Lisinopril—dilated cardiomyopathy	0.00234	0.00242	CcSEcCtD
Methylphenidate—Somnolence—Furosemide—dilated cardiomyopathy	0.00234	0.00242	CcSEcCtD
Methylphenidate—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00232	0.00241	CcSEcCtD
Methylphenidate—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00228	0.00237	CcSEcCtD
Methylphenidate—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00228	0.00236	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00227	0.00235	CcSEcCtD
Methylphenidate—Fatigue—Furosemide—dilated cardiomyopathy	0.00227	0.00235	CcSEcCtD
Methylphenidate—Tremor—Lisinopril—dilated cardiomyopathy	0.00226	0.00235	CcSEcCtD
Methylphenidate—Constipation—Furosemide—dilated cardiomyopathy	0.00225	0.00233	CcSEcCtD
Methylphenidate—Pain—Furosemide—dilated cardiomyopathy	0.00225	0.00233	CcSEcCtD
Methylphenidate—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00224	0.00232	CcSEcCtD
Methylphenidate—Anaemia—Lisinopril—dilated cardiomyopathy	0.00223	0.00232	CcSEcCtD
Methylphenidate—Angioedema—Lisinopril—dilated cardiomyopathy	0.00221	0.00229	CcSEcCtD
Methylphenidate—Malaise—Lisinopril—dilated cardiomyopathy	0.00218	0.00226	CcSEcCtD
Methylphenidate—Vertigo—Lisinopril—dilated cardiomyopathy	0.00217	0.00225	CcSEcCtD
Methylphenidate—Syncope—Lisinopril—dilated cardiomyopathy	0.00217	0.00225	CcSEcCtD
Methylphenidate—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00217	0.00225	CcSEcCtD
Methylphenidate—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00216	0.00224	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00215	0.00223	CcSEcCtD
Methylphenidate—Palpitations—Lisinopril—dilated cardiomyopathy	0.00213	0.00221	CcSEcCtD
Methylphenidate—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00212	0.0022	CcSEcCtD
Methylphenidate—Cough—Lisinopril—dilated cardiomyopathy	0.00211	0.00219	CcSEcCtD
Methylphenidate—Urticaria—Furosemide—dilated cardiomyopathy	0.00209	0.00216	CcSEcCtD
Methylphenidate—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00208	0.00215	CcSEcCtD
Methylphenidate—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00208	0.00215	CcSEcCtD
Methylphenidate—Chest pain—Lisinopril—dilated cardiomyopathy	0.00206	0.00213	CcSEcCtD
Methylphenidate—Myalgia—Lisinopril—dilated cardiomyopathy	0.00206	0.00213	CcSEcCtD
Methylphenidate—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00206	0.00213	CcSEcCtD
Methylphenidate—Anxiety—Lisinopril—dilated cardiomyopathy	0.00205	0.00213	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00204	0.00212	CcSEcCtD
Methylphenidate—Discomfort—Lisinopril—dilated cardiomyopathy	0.00203	0.00211	CcSEcCtD
Methylphenidate—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00201	0.00209	CcSEcCtD
Methylphenidate—Confusional state—Lisinopril—dilated cardiomyopathy	0.00199	0.00206	CcSEcCtD
Methylphenidate—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00197	0.00204	CcSEcCtD
Methylphenidate—Oedema—Lisinopril—dilated cardiomyopathy	0.00197	0.00204	CcSEcCtD
Methylphenidate—Infection—Lisinopril—dilated cardiomyopathy	0.00196	0.00203	CcSEcCtD
Methylphenidate—Shock—Lisinopril—dilated cardiomyopathy	0.00194	0.00201	CcSEcCtD
Methylphenidate—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00194	0.00201	CcSEcCtD
Methylphenidate—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00193	0.002	CcSEcCtD
Methylphenidate—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00192	0.002	CcSEcCtD
Methylphenidate—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00192	0.00199	CcSEcCtD
Methylphenidate—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00191	0.00198	CcSEcCtD
Methylphenidate—Asthenia—Furosemide—dilated cardiomyopathy	0.00189	0.00196	CcSEcCtD
Methylphenidate—Anorexia—Lisinopril—dilated cardiomyopathy	0.00188	0.00195	CcSEcCtD
Methylphenidate—Pruritus—Furosemide—dilated cardiomyopathy	0.00186	0.00193	CcSEcCtD
Methylphenidate—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0018	0.00186	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.0018	0.00186	CcSEcCtD
Methylphenidate—Insomnia—Lisinopril—dilated cardiomyopathy	0.00178	0.00185	CcSEcCtD
Methylphenidate—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00177	0.00184	CcSEcCtD
Methylphenidate—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00176	0.00182	CcSEcCtD
Methylphenidate—Somnolence—Lisinopril—dilated cardiomyopathy	0.00175	0.00182	CcSEcCtD
Methylphenidate—Dizziness—Furosemide—dilated cardiomyopathy	0.00174	0.0018	CcSEcCtD
Methylphenidate—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00174	0.0018	CcSEcCtD
Methylphenidate—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00171	0.00178	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.0017	0.00177	CcSEcCtD
Methylphenidate—Fatigue—Lisinopril—dilated cardiomyopathy	0.0017	0.00176	CcSEcCtD
Methylphenidate—Pain—Lisinopril—dilated cardiomyopathy	0.00169	0.00175	CcSEcCtD
Methylphenidate—Constipation—Lisinopril—dilated cardiomyopathy	0.00169	0.00175	CcSEcCtD
Methylphenidate—Vomiting—Furosemide—dilated cardiomyopathy	0.00167	0.00173	CcSEcCtD
Methylphenidate—Rash—Furosemide—dilated cardiomyopathy	0.00166	0.00172	CcSEcCtD
Methylphenidate—Dermatitis—Furosemide—dilated cardiomyopathy	0.00166	0.00172	CcSEcCtD
Methylphenidate—Headache—Furosemide—dilated cardiomyopathy	0.00165	0.00171	CcSEcCtD
Methylphenidate—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00162	0.00168	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00161	0.00167	CcSEcCtD
Methylphenidate—Urticaria—Lisinopril—dilated cardiomyopathy	0.00157	0.00162	CcSEcCtD
Methylphenidate—Nausea—Furosemide—dilated cardiomyopathy	0.00156	0.00162	CcSEcCtD
Methylphenidate—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00156	0.00162	CcSEcCtD
Methylphenidate—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00156	0.00162	CcSEcCtD
Methylphenidate—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00145	0.00151	CcSEcCtD
Methylphenidate—Asthenia—Lisinopril—dilated cardiomyopathy	0.00141	0.00147	CcSEcCtD
Methylphenidate—Pruritus—Lisinopril—dilated cardiomyopathy	0.00139	0.00145	CcSEcCtD
Methylphenidate—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00135	0.0014	CcSEcCtD
Methylphenidate—Dizziness—Lisinopril—dilated cardiomyopathy	0.0013	0.00135	CcSEcCtD
Methylphenidate—Vomiting—Lisinopril—dilated cardiomyopathy	0.00125	0.0013	CcSEcCtD
Methylphenidate—Rash—Lisinopril—dilated cardiomyopathy	0.00124	0.00129	CcSEcCtD
Methylphenidate—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00124	0.00129	CcSEcCtD
Methylphenidate—Headache—Lisinopril—dilated cardiomyopathy	0.00124	0.00128	CcSEcCtD
Methylphenidate—Nausea—Lisinopril—dilated cardiomyopathy	0.00117	0.00121	CcSEcCtD
